Stocks Funds Screener Sectors Watchlists

ME - 23andMe Holding Co. Stock Price, Fair Value and News

$4.00

Market Closed as of 11 Aug 2025, 04:00 pm ET

ME Stock Valuation Analysis

Valuation

Max Portfolio %

ME Price Action

ME RSI Chart

ME Stock Valuation Analysis

Valuation

Max Portfolio %

ME Valuation

ME Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ME Fundamentals

ME Revenue

ME Earnings

ME Profitability

ME Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	189.9M	174.9M	0	0
2024	219.6M	199.2M	193.3M	208.8M
2023	299.5M	295.8M	270.2M	248.0M
2022	271.9M	277.2M	297.6M	307.7M
2021	243.9M	255.1M	258.5M	259.9M
2020	305.5M	290.1M	274.7M	259.3M
2019	440.9M	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

CEO	Ms. Anne Wojcicki
WEBSITE	23andme.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	758